PURPOSE: The notch pathway is overexpressed in pancreatic adenocarcinoma. RO4929097, an oral inhibitor of the γ-secretase enzyme has been safely given as a single agent in patients with advanced solid tumors. We aimed to evaluate the efficacy of RO4929097 in patients with pancreatic adenocarcinoma (PDA). METHODS: A two-stage, single-arm Phase II trial was conducted in patients with previously treated metastatic PDA. RO4929097 was administered at a dose of 20 mg daily on days 1-3, 8-10 and 15-17 of 21-day cycles. The primary endpoint was survival at 6 months. Secondary endpoints included overall survival (OS), response rate, toxicities, pharmacokinetic and pharmacodynamic analyses. RESULTS: Eighteen patients were recruited, 17 in the first stage and one in the 2nd stage. It was decided to stop further enrollment after RO4929097 was discontinued by the sponsor and was no longer a development candidate. Three (25 %) of 12 evaluable patients achieved stable disease. The 6-month survival rate was 27.8 % (95 % CI 9.7-53.5). The median OS was 4.1 months (95 % CI 2.7-5.8 months) and median progression-free survival was 1.5 months (95 % CI 1.3-1.6 months). Pharmacokinetic properties of RO4929097 in patients (n = 5) with PDA was similar to that previously reported in other patient populations. There was a trend towards a decrease in HeyL (p = 0.08) gene expression in three patients following study drug administration. CONCLUSIONS: RO4929097 was well-tolerated in patients with previously treated PDA. Development of RO4929097 has been discontinued, but development of other notch-targeting agents in pancreatic cancer is continuing.
PURPOSE: The notch pathway is overexpressed in pancreatic adenocarcinoma. RO4929097, an oral inhibitor of the γ-secretase enzyme has been safely given as a single agent in patients with advanced solid tumors. We aimed to evaluate the efficacy of RO4929097 in patients with pancreatic adenocarcinoma (PDA). METHODS: A two-stage, single-arm Phase II trial was conducted in patients with previously treated metastatic PDA. RO4929097 was administered at a dose of 20 mg daily on days 1-3, 8-10 and 15-17 of 21-day cycles. The primary endpoint was survival at 6 months. Secondary endpoints included overall survival (OS), response rate, toxicities, pharmacokinetic and pharmacodynamic analyses. RESULTS: Eighteen patients were recruited, 17 in the first stage and one in the 2nd stage. It was decided to stop further enrollment after RO4929097 was discontinued by the sponsor and was no longer a development candidate. Three (25 %) of 12 evaluable patients achieved stable disease. The 6-month survival rate was 27.8 % (95 % CI 9.7-53.5). The median OS was 4.1 months (95 % CI 2.7-5.8 months) and median progression-free survival was 1.5 months (95 % CI 1.3-1.6 months). Pharmacokinetic properties of RO4929097 in patients (n = 5) with PDA was similar to that previously reported in other patient populations. There was a trend towards a decrease in HeyL (p = 0.08) gene expression in three patients following study drug administration. CONCLUSIONS: RO4929097 was well-tolerated in patients with previously treated PDA. Development of RO4929097 has been discontinued, but development of other notch-targeting agents in pancreatic cancer is continuing.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Yoshiharu Miyamoto; Anirban Maitra; Bidyut Ghosh; Ulrich Zechner; Pedram Argani; Christine A Iacobuzio-Donahue; Virote Sriuranpong; Tatsuya Iso; Ingrid M Meszoely; Michael S Wolfe; Ralph H Hruban; Douglas W Ball; Roland M Schmid; Steven D Leach Journal: Cancer Cell Date: 2003-06 Impact factor: 31.743
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Zhiwei Wang; Asfar Sohail Azmi; Aamir Ahmad; Sanjeev Banerjee; Shaomeng Wang; Fazlul H Sarkar; Ramzi M Mohammad Journal: Cancer Res Date: 2009-03-24 Impact factor: 12.701
Authors: Jonathan R Strosberg; Timothy Yeatman; Jill Weber; Domenico Coppola; Michael J Schell; Gang Han; Khaldoun Almhanna; Richard Kim; Tiffany Valone; Helen Jump; Dan Sullivan Journal: Eur J Cancer Date: 2012-03-23 Impact factor: 9.162
Authors: Anthony W Tolcher; Wells A Messersmith; Stanislaw M Mikulski; Kyriakos P Papadopoulos; Eunice L Kwak; Darlene G Gibbon; Amita Patnaik; Gerald S Falchook; Arvind Dasari; Geoffrey I Shapiro; John F Boylan; Zhi-Xin Xu; Ka Wang; Astrid Koehler; James Song; Steven A Middleton; Jonathan Deutsch; Mark Demario; Razelle Kurzrock; Jennifer J Wheler Journal: J Clin Oncol Date: 2012-04-23 Impact factor: 44.544
Authors: S Sahebjam; P L Bedard; V Castonguay; Z Chen; M Reedijk; G Liu; B Cohen; W-J Zhang; B Clarke; T Zhang; S Kamel-Reid; H Chen; S P Ivy; A R A Razak; A M Oza; E X Chen; H W Hirte; A McGarrity; L Wang; L L Siu; S J Hotte Journal: Br J Cancer Date: 2013-07-18 Impact factor: 7.640
Authors: Suzanne Richter; Philippe L Bedard; Eric Xueyu Chen; Blaise A Clarke; Ben Tran; Sebastien J Hotte; Anastasios Stathis; Hal W Hirte; Albiruni R A Razak; Michael Reedijk; Zhuo Chen; Brenda Cohen; Wen-Jiang Zhang; Lisa Wang; S Percy Ivy; Malcolm J Moore; Amit M Oza; Lillian L Siu; Elaine McWhirter Journal: Invest New Drugs Date: 2013-05-05 Impact factor: 3.850
Authors: Christoforos Kosmidis; Konstantinos Sapalidis; Efstathios Kotidis; Nikolaos Mixalopoulos; Paul Zarogoulidis; Drosos Tsavlis; Sofia Baka; Yan-Gao Man; John Kanellos Journal: Ann Transl Med Date: 2016-05
Authors: Tyler R McCaw; Evelyn Inga; Herbert Chen; Renata Jaskula-Sztul; Vikas Dudeja; James A Bibb; Bin Ren; J Bart Rose Journal: Oncologist Date: 2021-01-02
Authors: Jonathan Stem; John C Flickinger; Dante Merlino; Ellen M Caparosa; Adam E Snook; Scott A Waldman Journal: Regen Med Date: 2019-04-26 Impact factor: 3.806
Authors: KyeongJin Kim; Ira J Goldberg; Mark J Graham; Meenakshi Sundaram; Enrico Bertaggia; Samuel X Lee; Li Qiang; Rebecca A Haeusler; Daniel Metzger; Pierre Chambon; Zemin Yao; Henry N Ginsberg; Utpal B Pajvani Journal: Cell Metab Date: 2018-03-22 Impact factor: 27.287